Geron (GERN) Retained Earnings (2010 - 2026)
Geron (GERN) posted Retained Earnings of -$1.9 billion for Q1 2026, down 691357.62% sequentially from $269000.0 in Q4 2025, and down 3.76% YoY from -$1.9 billion in Q1 2025.
Geron (GERN) Retained Earnings (2010 - 2026) Analysis & Trends
Geron has reported Retained Earnings for 17 years, with the latest figure at -$1.9 billion in Q1 2026.
- Quarterly Retained Earnings fell 3.76% year-over-year to -$1.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.9 billion (down 3.76% YoY) and the FY2025 annual result came in at $269000.0, up 100.02% from the prior year.
- Retained Earnings eased to -$1.9 billion in Q1 2026 per GERN's latest filing, from $269000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $269000.0 in Q4 2025 and troughed at -$1.9 billion in Q1 2026.
- A 5-year average of -$985.2 million and a median of -$1.4 billion in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings slumped 8568893.75% in 2022, then jumped 184.47% in 2023.
- Over 5 years, Retained Earnings stood at -$219000.0 in 2022, then jumped by 184.47% to $185000.0 in 2023, then slumped by 958122.16% to -$1.8 billion in 2024, then soared by 100.02% to $269000.0 in 2025, then plunged by 691357.62% to -$1.9 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.9 billion, $269000.0, and -$1.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 4.38 Bn |
| 10 | Geron | 1.01 Mn | -299.84 Mn | - | -1.88 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.88 Bn |
| Mar 31, 2026 | -1.86 Bn |
| Dec 31, 2025 | 269,000.00 |
| Sep 30, 2025 | -1.83 Bn |
| Jun 30, 2025 | -1.81 Bn |
| Mar 31, 2025 | -1.79 Bn |
| Dec 31, 2024 | -1.77 Bn |
| Sep 30, 2024 | -1.75 Bn |
| Jun 30, 2024 | -1.72 Bn |
| Mar 31, 2024 | -273,000.00 |
| Dec 31, 2023 | 185,000.00 |
| Sep 30, 2023 | -1.55 Bn |
| Jun 30, 2023 | -945,000.00 |
| Mar 31, 2023 | -160,000.00 |
| Dec 31, 2022 | -219,000.00 |
| Sep 30, 2022 | -1.37 Bn |
| Jun 30, 2022 | -782,000.00 |
| Mar 31, 2022 | -1.30 Bn |
| Dec 31, 2021 | -173,000.00 |
| Sep 30, 2021 | 16,000.00 |